Article
Biochemistry & Molecular Biology
Martha Lucia Diaz, Karl Burgess, Richard Burchmore, Maria Adelaida Gomez, Sergio Alejandro Gomez-Ochoa, Luis Eduardo Echeverria, Carlos Morillo, Clara Isabel Gonzalez
Summary: This exploratory study used metabolomic profiling to investigate the underlying pathogenic mechanisms in the failing myocardium of patients with end-stage heart failure secondary to chronic Chagas cardiomyopathy (CCC). The results revealed altered metabolite profiles associated with energy deficit, changes in substrate availability, and increased production of reactive oxygen species in the affected myocardium.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Dominic Emerson, Joanna Chikwe, Pedro Catarino, Mohamed Hassanein, Luqin Deng, Ryan S. Cantor, Amy Roach, Robert Cole, Fardad Esmailian, Jon Kobashigawa, Jaime Moriguchi, James K. Kirklin
Summary: In contemporary practice, elderly patients receiving LVADs showed improved survival, increased functional capacity, enhanced quality of life, and fewer complications compared with younger patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Oncology
Jan M. Grif, Julie L. Rosenthal, Justin L. Grodin, Mathew S. Maurer, Martha Grogan, Richard K. Cheng
Summary: Transthyretin cardiac amyloidosis (ATTR-CA) is being diagnosed more frequently due to advancements in imaging technology and increased awareness. Despite the incomplete clinical penetrance of pathogenic alleles, there is a large population of asymptomatic transthyretin variant carriers. Effective therapies for ATTR-CA have emerged from a better understanding of its pathophysiology, with strategies focusing on transthyretin protein stabilization and silencing. Limited data exists on neurohormonal blockade in ATTR-CA, with current medical therapy primarily centered around careful fluid management.
JACC: CARDIOONCOLOGY
(2021)
Article
Oncology
Connor G. O'Brien, Mehmet Ozgun Ozen, Gentaro Ikeda, Evgeniya Vaskova, Ji Hye Jung, Nathan Bayardo, Michelle Rai Santoso, Liye Shi, Christine Wahlquist, Zewen Jiang, Yunshin Jung, Yitian Zeng, Elizabeth Egan, Robert Sinclair, Adrian Gee, Ronald Witteles, Mark Mercola, Katrin J. Svensson, Utkan Demirci, Phillip C. Yang
Summary: This study evaluated the efficacy and mechanisms of MSCs in treating DOX injury using patient-specific iCMs. Results showed that L-EVs derived from MSCs mediated mitochondrial transfer to mitigate DOX injury in patient-specific iCMs.
JACC: CARDIOONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Yu-Jen Chen, Chian-Shiu Chien, Chern-En Chiang, Chen-Huan Chen, Hao-Min Cheng
Summary: Heart failure is a syndrome caused by various important etiologies, and understanding genetic pathophysiology may lead to new therapies for improving HF prognosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Zheng Li, Yi Shi, Yiyuan Xia, Lida Wu, Hui Li, Rong Zhou, Xiaofei Gao, Hongsong Zhang, Xiaoping Jin, Junxia Zhang
Summary: The study aims to explore the clinical characteristics and prognosis of diabetic patients with different types of heart failure. It was found that compared to patients with HFrEF, patients with HFpEF had a shorter duration of type 2 diabetes, younger age, and were more likely to be associated with hypertension and non-obstructive coronary artery disease. Survival analysis showed that patients with HFpEF had a better composite endpoint prognosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Filippos Triposkiadis, Andrew Xanthopoulos, Alexandra Bargiota, Takeshi Kitai, Niki Katsiki, Dimitrios Farmakis, John Skoularigis, Randall C. Starling, Efstathios Iliodromitis
Summary: Diabetes mellitus is a major risk factor for new-onset heart failure, and vice versa. The pathogenesis of heart failure in diabetes is complex, involving toxic cardiovascular effects of hyperglycemia and metabolic abnormalities. The development of new-onset diabetes in heart failure patients, known as cardiogenic diabetes, is common and often related to insulin resistance.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Andreas Angelopoulos, Evangelos Oikonomou, Alexios S. Antonopoulos, Panagiotis Theofilis, Konstantinos Kalogeras, Paraskevi Papanikolaou, George Lazaros, Gerasimos Siasos, Dimitris Tousoulis, Konstantinos Tsioufis, Charalambos Vlachopoulos
Summary: This study aimed to identify factors related to heart failure symptoms and functional capacity in patients with hypertrophic cardiomyopathy (HCM). Patients were categorized based on functional capacity and symptoms, and echocardiographic measurements were conducted. The results showed that the symptomatic group had higher maximum LVOT gradient, RVSP, and E/e' ratio, and lower TASV compared to the asymptomatic group. Additionally, the RVAC calculated with the TASV/RVSP ratio was lower in the symptomatic group.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Yuya Miyamoto, Toru Kubo, Yuri Ochi, Yuichi Baba, Takayoshi Hirota, Naohito Yamasaki, Kazuya Kawai, Katsuhito Yamamoto, Fumiaki Kondo, Kanji Bando, Eisuke Yamada, Takashi Furuno, Toshikazu Yabe, Yoshinori L. Doi, Hiroaki Kitaoka
Summary: This study provides insights into the clinical features and incidence of heart failure in patients with hypertrophic cardiomyopathy in Japan. Atrial fibrillation, low percentage of fractional shortening, and high B-type natriuretic peptide level were identified as predictors of heart failure events. The study also categorized heart failure profiles into four types, each requiring specific treatment strategies.
CIRCULATION JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Yuya Miyamoto, Toru Kubo, Yuri Ochi, Yuichi Baba, Takayoshi Hirota, Naohito Yamasaki, Kazuya Kawai, Katsuhito Yamamoto, Fumiaki Kondo, Kanji Bando, Eisuke Yamada, Takashi Furuno, Toshikazu Yabe, Yoshinori L. Doi, Hiroaki Kitaoka
Summary: This study aimed to investigate the clinical features and event rates of heart failure in patients with hypertrophic cardiomyopathy (HCM) in Japan. The study found that atrial fibrillation, low percentage of fractional shortening, and high B-type natriuretic peptide level were predictors of heart failure events. There were different types of heart failure profiles among HCM patients. Close follow-up and appropriate treatment are necessary for these patients.
CIRCULATION JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Albert Topf, Moritz Mirna, Nina Bacher, Vera Paar, Lukas J. Motloch, Bernhard Ohnewein, Robert Larbig, Janine Grueninger, Uta C. Hoppe, Michael Lichtenauer, Rudin Pistulli
Summary: Among patients with diagnosed cardiomyopathy, the differentiation between Takotsubo cardiomyopathy (TTC) and ischemic cardiomyopathy (ICMP) or dilated cardiomyopathy (DCMP) can be challenging. Biomarkers such as sST-2 may play a crucial role in predicting and distinguishing these conditions.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Karen Sliwa, Johann Bauersachs, Zolt Arany, Timothy F. Spracklen, Denise Hilfiker-Kleiner
Summary: Peripartum cardiomyopathy is a global disease that should be suspected in peripartum women with symptoms of heart failure. Urgent cardiac investigations and referral to a cardiology team for expert management are crucial. Advances in genetics, pathophysiology, diagnostic approach, management, and outcome have been achieved in understanding PPCM.
EUROPEAN HEART JOURNAL
(2021)
Review
Cardiac & Cardiovascular Systems
Karen Sliwa, Johann Bauersachs, Zolt Arany, Timothy F. Spracklen, Denise Hilfiker-Kleiner
Summary: Peripartum cardiomyopathy is a globally occurring disease that should be suspected in women during the peripartum period. The disease has significant maternal and neonatal morbidity and mortality rates, with nearly half of patients experiencing myocardial recovery. Team efforts and expert management are crucial in the diagnosis and treatment of this condition.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Dan Tong, Gabriele G. Schiattarella, Nan Jiang, Francisco Altamirano, Pamela A. Szweda, Abdallah Elnwasany, Dong I. Lee, Heesoo Yoo, David A. Kass, Luke I. Szweda, Sergio Lavandero, Eric Verdin, Thomas G. Gillette, Joseph A. Hill
Summary: The study demonstrated through a mouse model that HFpEF is associated with myocardial mitochondrial dysfunction, and NAD(+) supplementation is considered a promising therapeutic approach.
CIRCULATION RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Heidi S. Lumish, Lusha W. Liang, Kohei Hasegawa, Mathew S. Maurer, Michael A. Fifer, Muredach P. Reilly, Yuichi J. Shimada
Summary: This study developed a plasma proteomics-based model to predict worsening heart failure in patients with hypertrophic cardiomyopathy (HCM). The model showed high accuracy and identified the Ras-MAPK and related signalling pathways as potential underlying mechanisms.
Article
Cardiac & Cardiovascular Systems
Jordi Coste Pradas, Gaelle Auguste, Scot J. Matkovich, Raffaella Lombardi, Suet Nee Chen, Tyrone Garnett, Kyle Chamberlain, Jalish Mahmud Riyad, Thomas Weber, Sanjay K. Singh, Matthew J. Robertson, Cristian Coarfa, Ali J. Marian, Priyatansh Gurha
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2020)
Article
Cardiac & Cardiovascular Systems
Leila Rouhi, Sirisha M. Cheedipudi, Suet Nee Chen, Siyang Fan, Raffaella Lombardi, Xiaofan Chen, Cristian Coarfa, Matthew J. Robertson, Priyatansh Gurha, Ali J. Marian
Summary: The study identified that TMEM43 haploinsufficiency leads to activation of the DDR and TP53 pathways, resulting in increased expression of SASP and an age-dependent pro-fibrotic cardiomyopathy. The shared mechanism in the pathogenesis of cardiomyopathies caused by mutations involving nuclear envelope proteins may involve DNA damage response.
CARDIOVASCULAR RESEARCH
(2021)
Review
Cardiac & Cardiovascular Systems
Ali J. Marian
Summary: COVID-19 is caused by SARS-CoV-2, and scientists have been able to develop therapies and vaccines based on previous research on SARS-CoV and MERS-CoV. By studying the structure and proteins of SARS-CoV-2, researchers have successfully developed vaccines and antiviral therapies for COVID-19.
CARDIOVASCULAR PATHOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Ping Yuan, Sirisha M. Cheedipudi, Leila Rouhi, Siyang Fan, Lukas Simon, Zhongming Zhao, Kui Hong, Priyatansh Gurha, Ali J. Marian
Summary: In a mouse model of ACM, epicardial-derived cardiac fibroblasts and epithelial cells express paracrine factors, including TGF beta 1 and fibroblast growth factors, which mediate epithelial-mesenchymal transition and contribute to myocardial fibrosis, apoptosis, arrhythmias, and cardiac dysfunction.
Article
Cardiac & Cardiovascular Systems
A. J. Marian
Summary: Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by left ventricular hypertrophy and may lead to heart failure or sudden cardiac death. Pathogenic variants in genes encoding myocardial protein constituents, especially MYH7 and MYBPC3 genes, are the main causes of HCM. Advances in genetic testing and drug development have improved the therapeutic prospects for HCM.
CIRCULATION RESEARCH
(2021)
Article
Multidisciplinary Sciences
Suet Nee Chen, Chi Keung Lam, Ying-Wooi Wan, Shanshan Gao, Olfat A. Malak, Shane Rui Zhao, Raffaella Lombardi, Amrut Ambardekar, Michael R. Bristow, Joseph Cleveland, Marta Gigli, Gianfranco Sinagra, Sharon Graw, Matthew R. G. Taylor, Joseph C. Wu, Luisa Mestroni
Summary: FLNC truncating mutations (FLNCtv) are common causes of inherited dilated cardiomyopathy (DCM) with a high risk of arrhythmogenic cardiomyopathy. This study used patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to investigate the molecular mechanisms of mutant FLNC in arrhythmogenic DCM. The researchers found that FLNC deficiency led to nuclear translocation of beta-catenin (CTNNB1) and activation of the platelet-derived growth factor receptor alpha (PDGFRA) pathway, which were also observed in human hearts with a-DCM and FLNCtv. Treatment with PDGFRA inhibitor improved contractile function of patient iPSC-CMs.
Editorial Material
Cardiac & Cardiovascular Systems
Ali J. Marian
CARDIOVASCULAR RESEARCH
(2022)
Review
Cardiac & Cardiovascular Systems
Michele Iavarone, Emanuele Monda, Olga Vritz, Dimpna Calila Albert, Marta Rubino, Federica Verrillo, Martina Caiazza, Michele Lioncino, Federica Amodio, Natale Guarnaccia, Felice Gragnano, Raffaella Lombardi, Giovanni Esposito, Eduardo Bossone, Paolo Calabro, Maria Angela Losi, Giuseppe Limongelli
Summary: Several treatments have been proven safe and effective for hypertrophic cardiomyopathy, but none has shown the ability to modify the disease's natural progression or reduce maximal wall thickness. However, promising new therapeutic approaches like sarcomere modulators and gene therapy are being developed. Mavacamten, a sarcomere modulator, has shown improvement in various aspects of patients' conditions in a phase 3 trial. Gene therapy, although still in early stages, has the potential to revolutionize the treatment of hypertrophic cardiomyopathy by correcting genetic alterations. This review provides an overview of current therapies, discusses emerging approaches, and presents future perspectives.
ARCHIVES OF CARDIOVASCULAR DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Cristina Mazzaccara, Raffaella Lombardi, Bruno Mirra, Ferdinando Barretta, Maria Valeria Esposito, Fabiana Uomo, Martina Caiazza, Emanuele Monda, Maria Angela Losi, Giuseppe Limongelli, Valeria D'Argenio, Giulia Frisso
Summary: The detection of pathogenic mutations in cardiomyopathies and channelopathies has been enhanced through the use of next-generation sequencing (NGS) and the inclusion of uncommon genes in molecular testing.
Editorial Material
Cardiac & Cardiovascular Systems
Raffaella Lombardi, Suet Nee Chen
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Review
Medicine, General & Internal
Errico Federico Perillo, Grazia Canciello, Felice Borrelli, Gaetano Todde, Massimo Imbriaco, Leopoldo Ordine, Salvatore Di Napoli, Raffaella Lombardi, Giovanni Esposito, Maria-Angela Losi
Summary: Hypertrophic cardiomyopathy (HCM) is a genetic disease with a varied clinical presentation and prognosis. A subgroup of patients with HCM may develop a left ventricular (LV) apical aneurysm, which is characterized by dysfunctional movement in the apex area of the heart. The main mechanism of this complication is believed to be the high pressure inside the aneurysm, combined with reduced blood perfusion, leading to ischemia and myocardial injury. However, the effectiveness of preventative treatment options such as anticoagulation and intracardiac defibrillator is still uncertain.
Review
Cardiac & Cardiovascular Systems
Gaetano Todde, Grazia Canciello, Felice Borrelli, Errico Federico Perillo, Giovanni Esposito, Raffaella Lombardi, Maria Angela Losi
Summary: Left ventricular outflow obstruction (LVOTO) and diastolic dysfunction are the main characteristics of hypertrophic cardiomyopathy (HCM), which can be identified in more than half of HCM patients and are important factors for symptoms and prognosis. This review aims to clarify the mechanism, diagnosis, and therapeutic strategies for patients with obstructive HCM.
Review
Cardiac & Cardiovascular Systems
Felice Borrelli, Maria Angela Losi, Grazia Canciello, Gaetano Todde, Errico Federico Perillo, Leopoldo Ordine, Giulia Frisso, Giovanni Esposito, Raffaella Lombardi
Summary: Hypertrophic cardiomyopathy (HCM) is a common heritable cardiovascular disorder characterized by unexplained left ventricular hypertrophy (LVH). It is inherited as an autosomal dominant trait and mutations in sarcomere genes account for 40% of the cases. HCM patients can be categorized into sarcomeric-positive (Sarc+) and sarcomeric-negative (Sarc-) groups based on genetic screening, with rare cases of Sarc- HCM caused by non-sarcomeric gene mutations. This review aims to discuss the phenotypic and clinical differences between Sarc+ and Sarc- HCM and provide an overview of HCM caused by rare non-sarcomeric mutations.
Meeting Abstract
Cardiac & Cardiovascular Systems
Cason Marco, Maria-Angela Losi, Felice Borrelli, Chiara Calore, Grazia Canciello, Fiore Manganelli, Stefano Tozza, Luca Bello, Suet Nee Chen, Lingaonan He, Maria Bueno Marinas, Rudy Celeghin, Martina Perazzolo Marra, Gaetano Todde, Giulia Frisso, Matthew Taylor, Kalliopi Pilichou, Raffaella Lombardi